Neural Representations of Memory Transformation (MEM_TRANS)

August 10, 2026 updated by: Kirstin-Friederike Heise, Medical University of South Carolina

Task-based Synchronous Electroencephalography and Functional Magnetic Resonance Imaging (EEG-fMRI) to Explore Neural Representations of Memory Maintenance in the Aging Brain.

Investigators overarching goal is to provide evidence for the link between altered spatiotemporal (where and when) neural mechanisms and the extent of changed memory maintenance in healthy older adults and to identify potential neural markers of compensatory function (cognitive resource). Investigators preliminary studies suggest that healthy older adults, compared to younger adults, benefit behaviorally from increased coupling between frontal and parietal brain waves when retrieving and updating well-consolidated visuomotor sequence memory via stronger top-down cognitive control of memory maintenance. Thus, Investigators central hypothesis is that the dynamics across cortical and subcortical regions (i.e., spatiotemporal representations) during transitions between different levels of memory stability indicate the efficiency of memory maintenance. The rationale is that while temporal and spatial neural signatures carry distinct mechanistic information, the joint definition of spatial and temporal representations will allow the differentiation of compensatory versus neurodegenerative mechanisms.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

To investigate the spatiotemporal neural dynamics during memory maintenance mechanisms, healthy older adults will practice a computer-based online visuomotor sequence learning task over consecutive days until reaching a performance plateau. At the performance plateau, participants will undergo concurrent electroencephalography and magnetic resonance imaging (EEG-fMRI) while being exposed to a behavioral interference intervention to perturb the stability of the previously stored memory trace to extract spatiotemporal neural dynamics during these transitional states. Additionally, participants will undergo an additional brain scan to quantify aging-related neurodegeneration based on grey- and white-matter integrity, cerebral perfusion, and resting-state connectivity. Cognitive functioning and putative confounders of learning and memory will be quantified with standardized assessments. The experimental procedures include an individual number of daily computer-based sessions of task practice at home, and two lab visits including questionnaires, neuropsychological testing, and two MRI brain scans distributed over approximately two weeks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Principal Investigator
  • Phone Number: (843)792-3435
  • Email: heisek@musc.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthy volunteers aged18 years or older (80 of the final sample will be ≥60years of age).

Description

Inclusion Criteria:

  • Age 18 years or older (80 of the final sample will be ≥60years of age)
  • Cognitively unimpaired, ambiguous, or mildly impaired cognitive function, defined as a score of ≥18 in the Montreal Cognitive Assessment (MOCA).
  • No previous stroke, brain tumor, neurodegenerative disease, or trauma to the head
  • Ability to give consent for study participation
  • Ability to perform a computer task requiring responding to visual cues and typing on a standard computer keyboard with both index and middle fingers for 30 minutes daily.

Exclusion Criteria:

  • Inability to use both index and middle fingers to type on a standard computer keyboard
  • Dementia defined as a score of <18 in the Montreal Cognitive Assessment (MOCA)
  • Uncorrected vision, hindering perception of visual cues presented on a standard computer screen
  • Medication use at the time of study that may interfere with learning, including but not limited to carbamazepine, flunarizine, sulpiride, rivastigmine, and dextromethorphan.
  • Neuromuscular disorders that affect fine motor control of the hands.
  • Presence of neurological or psychiatric disorders
  • Presence of scalp injury or disease
  • Prior intracranial surgery
  • Prior brain radiotherapy
  • Prior history of intracranial tumor, intracranial infection, or cerebrovascular malformation
  • Metal in the head or neck
  • Contraindications to MRI (such as severe claustrophobia, implanted medical devices)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
behavioral skill learning intervention
All participants in this study undergo daily practice of a new skill until change through practice stabilizes (plateau).
Behavioral: Computer-based visuomotor sequence learning and interference
The behavioral sequence learning and interference paradigm allows the experimental manipulation of sequence memory after long-term consolidation achieved through individualized longitudinal practice and serves the extraction of the primary behavioral outcome. The learning task requires participants to respond with keypresses on a standard computer keyboard of visual targets. Participants will implicitly (without being made aware) learn sequential regularities provided through the recurring order of cued keys contrasted with random keys. Participants will practice the learning task remotely over consecutive days until a stable performance plateau is reached. During this phase, data will be collected online, and behavioral change will be monitored in real time. Then participants will undergo the behavioral interference intervention, in which the initially learned sequence memory will be perturbed through (implicit) exposure to new sequential information (i.e., interference).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in relative performance precision
Time Frame: 60 minutes
The primary behavioral outcome parameter is based on the precision of keypresses, i.e., temporal and spatial deviation of pressed from cued keys measured in a single compound measure [actual precision in %] serve to describe behavior across retrieval of formerly consolidated and interference with competing new sequential information.
60 minutes
Whole-brain change in time-resolved neural dynamics extracted EEG (temporal representations).
Time Frame: 60 minutes
Temporal patterns of brain dynamics derived from electroencephalography and projected into the anatomical source space serve to describe the temporal representations across retrieval of formerly consolidated and interference with competing new sequential information.
60 minutes
Change in blood-oxygenation-level-dependent (BOLD) derived brain activation patterns (spatial representations)
Time Frame: 60 minutes
Change of spatially precise whole-brain blood-oxygenation-level-dependent (BOLD) signal changes (spatial representations) across retrieval of formerly consolidated and interference with competing new sequential information.
60 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Medical University of South Carolina

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institutes of Health (NIH)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Kirstin-Friederike Heise, PhD, Medical University of South Carolina

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 30, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 25, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 3, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 6, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 10, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Pro00141769

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings